Trial Profile
A pilot clinical trial with the iron chelator Deferiprone in Parkinson's disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Jun 2020
Price :
$35
*
At a glance
- Drugs Deferiprone (Primary)
- Indications Iron metabolism disorders; Parkinson's disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms DeferipronPD
- 01 Mar 2012 New source identified and integrated (ClinicalTrials.gov NCT01539837).
- 17 Nov 2011 New trial record